Lantern Pharma(US:LTRN)2026-03-30 21:35Financial Performance - Lantern Pharma reported a 19% reduction in total operating expenses year-over-year while advancing multiple clinical programs[4]. - Research and development expenses for the year ended December 31, 2025, were approximately $11.5 million, a decrease of 29% from $16.1 million in 2024[33]. - General and administrative expenses increased by approximately 6% to $6.5 million for the year ended December 31, 2025, compared to $6.1 million in 2024[34]. - The net loss for the year ended December 31, 2025, was approximately $17.1 million, representing an 18% reduction from a net loss of $20.8 million in 2024[35]. - Cash, cash equivalents, and marketable securities totaled approximately $10.1 million as of December 31, 2025, down from $24.0 million as of December 31, 2024[32]. - The company sold 356,922 shares under its ATM Sales Agreement for gross proceeds of $1.6 million during the year ended December 31, 2025[39]. - The company will need to secure substantial additional funding in the near future to support its operations and clinical advancements[32]. Clinical Trials and Developments - The LP-300 Phase 2 HARMONIC™ trial achieved an 86% clinical benefit rate and a 43% objective response rate in initial safety lead-in cohorts[12]. - The LP-184 Phase 1a trial achieved a 48% clinical benefit rate at or above the therapeutic dose threshold, with plans to advance to Phase 1b/2 trials[13]. - The proposed amendments to the HARMONIC™ study include increasing the maximum treatment cycles from six to eight and focusing on patients with EGFR exon 21 L858R mutations[9]. - The company plans to initiate multiple clinical trials in 2026, including LP-184 Phase 1b/2 trials in TNBC and NSCLC, subject to funding[49]. Market Opportunities - Lantern's clinical pipeline has an estimated annual market potential exceeding $15 billion, with multiple programs advancing towards key milestones in 2026[5]. - The global market opportunity for never-smoker NSCLC is estimated at over $4 billion annually, with no approved therapies currently available[11]. - Lantern anticipates a potential near-term market opportunity of $20 to $50 billion for its AI platforms, aiming to capture a meaningful share of this market[28]. - The estimated annual market potential for the company's AI-driven pipeline of innovative product candidates exceeds $15 billion[48]. AI Platforms and Innovations - The RADR® AI platform's global expansion includes the establishment of an AI Center of Excellence in India to enhance biopharma development opportunities[20]. - The withZeta.ai platform is in active demo and beta testing with over 25 biotech companies, representing a significant near-term commercialization opportunity[22]. - The AI platform predictBBB.ai achieved 94.1% accuracy for blood-brain barrier permeability prediction, enhancing its molecular and structural analysis capabilities[30]. - The LBx-AI Liquid Biopsy tool demonstrated 86% accuracy in predicting treatment response in NSCLC[30]. Communication and Disclosure - Lantern Pharma disseminates material information through various channels including its website, press releases, SEC filings, digital newsletters, and social media[54]. - Investors are encouraged to review publicly available information as it may contain material insights about the company[54]. - The list of disclosure channels may be updated periodically[54].